Fig. 3From: Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trialsPercentages of patients with ≥50% and ≥75% reductions in migraine headache days, by age groupBack to article page